Selective deletion of antigen-specific, activated T cells by a humanized mab to CD2 (medi-507) is mediated by NK cells

被引:36
作者
Branco, L
Barren, P
Mao, SY
Pfarr, D
Kaplan, R
Postema, C
Langerman, S
Koenig, S
Johnson, S
机构
[1] Medimmune Inc, Dept Immunol & Mol Genet, Gaithersburg, MD 20878 USA
[2] BioTransplant Inc, Dept Biol Mol, Cambridge, MA 02139 USA
关键词
D O I
10.1097/00007890-199911270-00026
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CD2 is a 50-kDa transmembrane glycoprotein that plays an important role in T and natural killer (NT) lymphocyte functions. CD2 serves as both an adhesion molecule and as a costimulatory molecule through interactions with its ligand, CD58, on antigen presenting or target cells. Consistent with earlier studies using a rat anti-CD2 mAb, we have shown that treatment of alloantigen stimulated T lymphocytes with a humanized mAb, MEDI-507 (IgG1, kappa), induced hyporesponsiveness to subsequent stimulation with alloantigen but not mitogen (phytohemagglutinin). Fluorescence-activated cell sorting analysis of cells from mixed lymphocyte reaction (MLR) treated with MEDI-507 revealed pronounced deletion of T and NIC cells, consistent with lack of proliferation in the MLR. MEDI-507 F(ab')(2) fragments did not have inhibitory activity or induce deletion of lymphocytes in the MLR, Removal of the NR, cell subset by magnetic bead depletion using anti-CD16 and anti-CD56 mAbs eliminated both the T cell deletion and the inhibitory effect. Reconstitution of NK depleted responder populations using autologous NK cells restored the MEDI-507-mediated deletion activity to levels measured in the original MLR. Formaldehyde-fixed NK cells failed to mediate the MEDI-507-induced deletion effect. Altogether, our studies indicate that activated T cells with MEDI-507 bound to CD2 are preferential targets for autologous NK cells through a nonapoptotic cytotoxic mechanism.
引用
收藏
页码:1588 / 1596
页数:9
相关论文
共 28 条
[1]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[2]  
BAZIN H, 1997, Patent No. 12645
[3]   MONOCLONAL-ANTIBODIES AGAINST HUMAN T-CELL ADHESION MOLECULES - MODULATION OF IMMUNE FUNCTION IN NONHUMAN-PRIMATES [J].
BERLIN, PJ ;
BACHER, JD ;
SHARROW, SO ;
GONZALEZ, C ;
GRESS, RE .
TRANSPLANTATION, 1992, 53 (04) :840-849
[4]  
Bierer B E, 1993, Semin Immunol, V5, P249, DOI 10.1006/smim.1993.1029
[5]   USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].
CALIFF, RM ;
SHADOFF, N ;
VALETT, N ;
BATES, E ;
GALEANA, A ;
KNOPF, W ;
SHAFTEL, J ;
BENDER, MJ ;
AVERSANO, T ;
RAQUENO, J ;
GURBEL, P ;
COWFER, J ;
COHEN, M ;
CROSS, P ;
BITTL, J ;
EDDINGS, K ;
TAYLOR, M ;
DEROSA, K ;
HATTEL, L ;
COOPER, L ;
ESHELMAN, B ;
FINTEL, D ;
NIEMYSKI, P ;
KLEIN, L ;
KENNEDY, H ;
THORNTON, T ;
KEREIAKES, D ;
MARTIN, L ;
ANDERSON, L ;
HIGBY, N ;
ELLIS, S ;
BREZINA, K ;
GEORGE, B ;
CHAPEKIS, A ;
SMITH, D ;
ANWAR, A ;
GERBER, TL ;
PRITCHARD, GL ;
MYLER, R ;
SHAW, R ;
MURPHY, M ;
WARD, K ;
MADIGAN, NP ;
BLANKENSHIP, J ;
HALBERT, M ;
FLANAGAN, C ;
TANNENBAUM, M ;
POLICH, M ;
STEVENSON, C ;
TCHENG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961
[6]   CD54/ICAM-1 IS A COSTIMULATOR OF NK CELL-MEDIATED CYTOTOXICITY [J].
CHONG, ASF ;
BOUSSY, IA ;
JIANG, XL ;
LAMAS, M ;
GRAF, LH .
CELLULAR IMMUNOLOGY, 1994, 157 (01) :92-105
[7]   The structure and ligand interactions of CD2: Implications for T-cell function [J].
Davis, SJ ;
vanderMerwe, PA .
IMMUNOLOGY TODAY, 1996, 17 (04) :177-187
[8]  
Delmonice FL, 1996, CLIN TRANSPLANT, V10, P397
[9]  
DENNING SM, 1987, J IMMUNOL, V139, P2573
[10]  
Dumont C, 1998, J IMMUNOL, V160, P3797